By analysing data through a more granular lens, including disaggregation by gender, we can uncover meaningful insights, identify differential responses, and ultimately drive more equitable outcomes for all patient groups. Doing so also supports alignment with regulatory expectations around inclusive and evidence based post-market surveillance.

Sabera Hyderally, Purdie Pascoe’s Head of US MedTech, recently facilitated an engaging, honest, and thought-provoking conversation with experts from across the MedTech and Diagnostics industry. The discussion explored how MedTech differs from other sectors, particularly pharmaceuticals, and what these differences mean for how we approach market research, innovation, and patient engagement. 

Attending this year’s RAPS Congress we were reminded of why we do what we do; at the heart of every conversation from regulatory reform to AI innovation there was one shared purpose: improving patients’ lives.

Are you attending the RAPS European Lifecycle Management Conference from 28-29 October? Purdie Pascoe’s Head of Post Market Surveys, Marcus Torr will be attending and presenting.

With over 50 of us now based across the UK, US, and Europe, this year’s meeting was a true celebration of our growth, our people, and our commitment to MedTech. Fittingly, our theme this year was bold and simple: MedTech, as it’s not just one of our sectors - it’s our sole focus.

While quantitative data can reveal what is happening, qualitative insights uncover the why; shedding light on patient experiences, clinician workflows, and unmet needs that numbers alone can't capture. By diving deep into real-world perspectives, MedTech companies can design more intuitive devices, craft compelling value propositions, and navigate complex regulatory and reimbursement landscapes with greater confidence.

Post-Market Clinical Follow-up (PMCF) surveys can help address clinical data gaps that may impact the ongoing assessment of a medical device’s safety and performance. Unearthing clinical gaps requires a systematic approach, including a review of clinical literature, post-market surveillance data, and regulatory compliance standards.

As we navigate through the busy conference season, the industry is buzzing with innovation, networking, and knowledge sharing. Conferences are pivotal events that drive advancements, offering a unique platform for professionals to stay ahead of the curve. However, the true value of these events lies in the insights they generate.

We are delighted to be attending MedDev Day from 13-14 October 2025 in Budapest. Purdie Pascoe’s Head of Post Market Surveys, Marcus Torr will be attending and presenting at the conference.

Our client, a market-leading provider of vascular surgery products for aortic and peripheral vascular disease, wanted to understand how they could better service interventional cardiologists (ICs) and their patients by understanding ICs’ preferences, perceptions, and influences and priorities.

We are delighted to be the exhibiting at the RAPS Convergence, 7-9 October 2025 in Pittsburgh, US. Purdie Pascoe’s Post Market Survey experts Ellie Baker, Commercial Director and Chris Webb Research Manager | RCC- MDR are exhibiting on Booth 817.

As the ctDNA cancer monitoring market becomes increasingly competitive, established panels continue to maintain their foothold amidst a surge of new entrants. Purdie Pascoe is conducting an ongoing syndicated study exploring the US ctDNA Cancer Monitoring Landscape. Waves 1 through 3 are available for immediate purchase, with Wave 4 launching soon.

Experts presenters from across the industry; Breda Kearny - Clinical Regulatory Lead, BSI, Diane M. Legere - Senior Clinical Auditor, DNV, Marcus Torr - Head of Post Market Surveys, Purdie Pascoe and Efsthathios Vassiliadis - CEO, Evnia.

In the fast-evolving world of medical technology, innovation alone isn’t enough. A brilliant device or digital therapeutic can fail if it doesn’t align with the needs of end users, clinical workflows, or regulatory pathways. That’s where market research steps in, not as a luxury, but as a strategic necessity.

On  2 August 2025, the second phase of the Act came into force, introducing new compliance standards for providers of general-purpose AI models. These updates mark a significant step in ensuring AI systems are not only powerful but also trustworthy. 

As MedTech professionals know, the industry rarely sleeps, but let’s be honest: in August, it definitely takes a nap. With inboxes a little quieter and decision-makers (hopefully) stealing a few hours in the sun, it’s the perfect time for some lighter reflection. So, grab your iced coffee (or something stronger), and let’s talk Post Market Surveys, from the poolside.

Partnering with an external team that understands and supports every stage of the MedTech journey can be transformative. In this conversation, leading experts share how Purdie Pascoe’s integrated expertise in Primary Market Research and Post Market Surveys is the true golden ticket to a seamless, compliant, and impactful approach for success in your MedTech journey.

Find out how we provided our client with a clear and effective path forward to help launch their pre-filled syringes for subcutaneous immunoglobulin therapy, and how best to position themselves for widespread adoption.

In this session, Breda Kearney, Clinical Regulatory Lead from BSI and Chris Webb, Research Manager and PMCF expert from Purdie Pascoe explore the correct application of Article 61(10) under the EU MDR and the critical role of PMCF surveys in supporting compliance.

In a world where many agencies claim to serve MedTech, very few are true specialists. MedTech isn’t just one of our sectors - it’s our sole focus. That’s what sets us apart. We’re proudly returning to our roots and doubling down on what we do best; helping companies like yours make smarter, faster, and more confident decisions.